Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Paratek Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapies for infectious diseases, particularly its lead product, NUZYRA (omadacycline), which is approved for the treatment of community-acquired bacterial pneumonia and skin infections. The company's competitive position is bolstered by its proprietary tetracycline platform, which allows for the development of novel antibiotics that address antibiotic resistance, a significant global health challenge.
Paratek generates revenue primarily through the sale of NUZYRA, leveraging its unique formulation and delivery method to address unmet medical needs in antibiotic therapy. The company benefits from pricing power due to the high demand for effective antibiotics amidst rising antibiotic resistance, and it has established partnerships for distribution to enhance market penetration.
Regulatory approvals for new indications of NUZYRA
Partnership agreements for expanded distribution
Market share growth in the antibiotic segment
Clinical trial results for pipeline products
Regulatory changes affecting drug approval processes
Technological disruption in antibiotic development
Emergence of generic competitors for NUZYRA
Increased competition from other novel antibiotics
Negative cash flow impacting liquidity
High operational costs without corresponding revenue growth
low - The demand for antibiotics is relatively inelastic, as they are essential for treating infections regardless of economic conditions.
Minimal impact from interest rates, as the company is not heavily reliant on debt financing and primarily funds operations through equity.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on credit for its operations.
growth - Investors looking for exposure to innovative biotech with potential for high returns from successful drug commercialization.
high - The stock has shown significant price fluctuations, reflecting the inherent risks and potential rewards in the biotech sector.
